You are viewing the site in preview mode

Skip to main content

Advertisement

Table 1 Baseline characteristics for Mitra Plus women on ART for life

From: Virologic and immunologic failure, drug resistance and mortality during the first 24 months postpartum among HIV-infected women initiated on antiretroviral therapy for life in the Mitra plus Study, Dar es Salaam, Tanzania

Characteristic All women (n = 84) Analyzed women (n = 73)
Age in years, median (IQR)* 29 (25–32) 29 (25–33)
Education years, median 7 7
Gravidity, median (IQR) 2 (1–3) 2 (2–3)
Parity, median (IQR) 1 (0–2) 1 (0–2)
Hemoglobin median (IQR) 9.9 (8.6-10.9) 9.9 (8.6-10.8)
CD4 count (cell/μL) at enrolment, median(IQR) 139 (95–173) 139 (98–174)
CD4 % at enrolment, median (IQR) 10 (6–13) 11 (6–13)
Viral load, median (IQR) 66,648 (15,253-193,182) 66,569 (15,051-195,289)
10 log Viral load mean 10.77 10.73
Karnofsky score, median (IQR) 92 (90–98) 92 (90–100)
WHO clinical stage at enrolment   
Stage 1 64/84 (76%) 55/73 (76%)
Stage 2 10/84 (12%) 9/73 (12%)
Stage 3 1/84 (1%) 1/73 (1%)
Stage 4 9/84 (11%) 8/73 (11%)
Marital status   
Married 44/84 (52%) 40/73 (55%)
Cohabiting 31/84 (37%) 26/73 (35%)
Not married 9/84 (11%) 7/73 (10%)
Disclosed HIV status to partner/relative   
No 69/83 (71%) 54/72 (75%)
Yes 24/83 (29%) 18/72 (25%)
Partner’s HIV status   
Negative 10/76 (13%) 10/66 (15%)
Positive 5/76 (7%) 5/66 (8%)
Not known 61/76 (80%) 51/66 (77%)
  1. *(IQR) indicates Inter Quartile Range.